Skip to content
TrialScanner

NCT05360238

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Phase 1/Phase 2TerminatedMBIOLead

Registry record

Lead sponsor
Mustang Bio
Conditions
Follicular B-cell Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma Recurrent; Mantle Cell Lymphoma Refractory; Small Lymphocytic Lymphoma, Relapsed; Waldenstrom's Macroglobulinemia Recurrent
Primary completion
Apr 12, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05360238 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.